Author (Corporate) | European Medicines Agency |
---|---|
Series Title | Press Release |
Series Details | EMA/CHMP/343656/2012 (25.5.12) |
Publication Date | 25/05/2012 |
Content Type | News |
The European Medicines Agency, on 25 May 2012, recommended Kalydeco (ivacaftor), an orphan-designated medicine, for the treatment of cystic fibrosis in patients age 6 years and older who have a G551D mutation in the cystic fibrosis transmembrane regulator (CFTR) gene. |
|
Source Link | Link to Main Source http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/05/news_detail_001520.jsp&mid=WC0b01ac058004d5c1 |
Related Links |
|
Subject Categories | Health |
Countries / Regions | Europe |